<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537823</url>
  </required_header>
  <id_info>
    <org_study_id>07-0182</org_study_id>
    <nct_id>NCT00537823</nct_id>
  </id_info>
  <brief_title>Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement</brief_title>
  <official_title>Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of short-duration pre-operative FOLFOX
      based therapy on postoperative problems after liver surgery for patients with metastatic
      colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although early stage, localized colon and rectal cancers are associated with 5 year survival
      rates of nearly 90%, only a minority of patients present with localized disease.
      Unfortunately, at the time of their initial presentation, approximately 35% of patients with
      colon or rectal cancer have metastatic disease. Nearly two thirds of these patients with
      stage IV disease have evidence of extrahepatic spread and have a median overall survival rate
      of 8-10 months in the absence of further treatment. Even with the most intensive
      chemotherapeutic regimens, the median overall survival for these patients ranges from 12
      months to 20 months. However, a small subset of patients with stage IV disease has isolated
      hepatic metastatic disease and can undergo resection. The patients with completely resected
      liver metastases enjoy a significantly higher overall five-year survival, which is as high as
      58% in carefully selected patients. Ten-year overall survival has been reported in 22% of
      patients. Despite this improvement, the five-year disease-free survival for these patients is
      at best 35%, with hepatic recurrences occurring in 46%.

      The fact that adjuvant chemotherapy improves the three-year survival rate for stage II
      disease and five-year survival rates for stage III disease implies that it can treat
      micrometastatic disease in some fraction of patients. Because micrometastatic disease is
      likely the cause of the high recurrence rate in patients who undergo liver resection, there
      is a clear biologic rationale for using postoperative adjuvant chemotherapy after liver
      resection. Although this strategy is a common practice in many centers, no convincing data
      that this improves survival have been reported. A large randomized phase III trial (EORTC
      40983) examining this question is currently ongoing and effect on survival has not yet been
      reported. Given that systemic chemotherapy after liver resection remains of unproven benefit
      at the present time, many have wondered if preoperative treatment might have more promise in
      improving recurrence rates.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual.
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Complication Rate</measure>
    <time_frame>30 days following surgery</time_frame>
    <description>Fraction of patients with any grade of complication I-V</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Postoperative Complication Rate</measure>
    <time_frame>30 days following surgery</time_frame>
    <description>Fraction of patients with any complication grades IV and V</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>30 days following surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Recurrence Patterns</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Liver only vs distant disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Hepatic Toxicity at Surgery</measure>
    <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonalcoholic Steatohepatitis Score (0-3)</measure>
    <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
    <description>NASH Scoring
Steatosis **&lt;5% = 0
**5-33%=1
**&gt;33-66%=2
**&gt;66%=3
Lobular inflammation
**No foci=0
**&lt;2 foci per x 200 field=1
**2-4 foci per x 200 field=2
**&gt;4 foci per x 200 field=3
Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Injury Scale Score (0-27)</measure>
    <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Preoperative Chemotherapy on Tumor Size</measure>
    <time_frame>Upon completion of neoadjuvant chemotherapy (approximately 2 months)</time_frame>
    <description>Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Size From Pretreatment to Preoperative CT Scan</measure>
    <time_frame>Completion of neoadjuvant therapy (approximately 8 weeks)</time_frame>
    <description>-Compare total longest diameter from baseline to preoperative CT scan.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastases</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Wildtype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 K-Ras 12/13 codon mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Arm 1 - Wildtype</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Arm 2 K-Ras 12/13 codon mutation</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Arm 1 - Wildtype</arm_group_label>
    <arm_group_label>Arm 2 K-Ras 12/13 codon mutation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Arm 1 - Wildtype</arm_group_label>
    <arm_group_label>Arm 2 K-Ras 12/13 codon mutation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <arm_group_label>Arm 1 - Wildtype</arm_group_label>
    <arm_group_label>Arm 2 K-Ras 12/13 codon mutation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Synchronous or metachronous colorectal metastases

          -  Technically resectable liver metastases

               -  Four or fewer metastases

               -  No tumors in porta hepatis

               -  Resection of no more than 70% of liver needed

          -  Medically suitable candidate for major liver resection

          -  FDG-PET scan without metastatic disease outside the liver

        Exclusion Criteria:

          -  Near-obstructing or obstructing colon lesions in patients in whom combined resection
             is planned (as delay for preoperative chemotherapy would be medially impossible)

          -  Treatment with FOLFOX or cetuximab within 12 months

          -  Treatment with irinotecan within 12 months

          -  Abnormal liver function (ALT or AST &gt; 5x ULN, bilirubin &gt; 3x ULN)

          -  Body mass index &gt;/= 35 kg/m² (as the risk for steatohepatitis is increased)

          -  Renal insufficiency (Cr &gt; 2.5mg/dL)

          -  Interstitial lung disease (because cetuximab has been rarely associated with
             development of interstitial lung disease)

          -  ECOG performance score &gt;/= 3

          -  Patients unable to give informed consent

          -  Pregnant patient (as cetuximab is a Class C drug)

          -  Peripheral neuropathy &gt;/= grade II (as oxaliplatin causes neuropathy to worsen)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Linehan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Adam R, Aloia T, Figueras J, Capussotti L, Poston G, Mentha G, Selzner M, and the LiverMetSurvey Scientific Committee. LiverMetSurvey: Analysis of clinicopathologic factors associated with the efficacy of preoperative chemotherapy in 2,122 patients with colorectal liver metastases. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3521.</citation>
  </reference>
  <reference>
    <citation>Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001 May;8(4):347-53.</citation>
    <PMID>11352309</PMID>
  </reference>
  <reference>
    <citation>Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.</citation>
    <PMID>16230673</PMID>
  </reference>
  <reference>
    <citation>André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51.</citation>
    <PMID>15175436</PMID>
  </reference>
  <reference>
    <citation>Badarinath S, Mitchell EP, Jennis A, Graham CD, Hansen VL, Henderson CA, Chen TT, Langer C. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3531.</citation>
  </reference>
  <reference>
    <citation>Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005 Dec 20;23(36):9073-8. Erratum in: J Clin Oncol. 2006 Apr 1;24(10):1648.</citation>
    <PMID>16361615</PMID>
  </reference>
  <reference>
    <citation>Capussotti L, Muratore A, Ferrero A, Massucco P, Ribero D, Polastri R. Randomized clinical trial of liver resection with and without hepatic pedicle clamping. Br J Surg. 2006 Jun;93(6):685-9.</citation>
    <PMID>16703653</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992 May;111(5):518-26.</citation>
    <PMID>1598671</PMID>
  </reference>
  <reference>
    <citation>Colucci G, Giuliani F, Mattioli R, Garufi C, Mallamaci R, Pezzella G, Lopez M, Maiello E. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale . Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3559.</citation>
  </reference>
  <reference>
    <citation>Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):337-45.</citation>
    <PMID>15269313</PMID>
  </reference>
  <reference>
    <citation>Dakhil S, Cosgriff T, Headley D, Badarinath S, International Oncology Network, R. V. Boccia. Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S, 2006: 3557</citation>
  </reference>
  <reference>
    <citation>D'Angelica M, Maddineni S, Fong Y, Martin RC, Cohen MS, Ben-Porat L, Gonen M, DeMatteo RP, Blumgart LH, Jarnagin WR. Optimal abdominal incision for partial hepatectomy: increased late complications with Mercedes-type incisions compared to extended right subcostal incisions. World J Surg. 2006 Mar;30(3):410-8.</citation>
    <PMID>16467983</PMID>
  </reference>
  <reference>
    <citation>Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005 Mar;16(3):425-9. Epub 2005 Jan 27.</citation>
    <PMID>15677624</PMID>
  </reference>
  <reference>
    <citation>Díaz Rubio E, JTabernero J, van Cutsem E, Cervantes A, André T, Humblet Y, Soulié P, Corretgé S, Kisker O,de Gramont A. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3535.</citation>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <reference>
    <citation>Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005 Aug 1;23(22):4853-5.</citation>
    <PMID>16051943</PMID>
  </reference>
  <reference>
    <citation>Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006 Feb;43(2 Suppl 1):S45-53. Review.</citation>
    <PMID>16447274</PMID>
  </reference>
  <reference>
    <citation>Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50.</citation>
    <PMID>15319715</PMID>
  </reference>
  <reference>
    <citation>Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005 Jun;200(6):845-53.</citation>
    <PMID>15922194</PMID>
  </reference>
  <reference>
    <citation>Finkelstein SE, Fernandez FG, Dehdashti F, Siegel BA, Hawkins WG, Linehan DC, Strasberg SM. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg. 2008;15(5):483-7. doi: 10.1007/s00534-007-1237-2. Epub 2008 Oct 4.</citation>
    <PMID>18836801</PMID>
  </reference>
  <reference>
    <citation>Gruenberger T, Sorbye H, Debois M, Bethe U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B. Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3500.</citation>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Ibrahim S, Chen CL, Wang CC, Wang SH, Lin CC, Liu YW, Yang CH, Yong CC, Concejero A, Cheng YF. Liver regeneration and splenic enlargement in donors after living-donor liver transplantation. World J Surg. 2005 Dec;29(12):1658-66.</citation>
    <PMID>16311869</PMID>
  </reference>
  <reference>
    <citation>Jennis A , J. Polikoff, E. Mitchell, S. Badarinath, C. Graham, T. Chen, T. Gustafson, C. Langer Erbitux (Cetuximab) Plus FOLFOX for Colorectal Cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3574</citation>
  </reference>
  <reference>
    <citation>Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006 Jan;243(1):1-7.</citation>
    <PMID>16371728</PMID>
  </reference>
  <reference>
    <citation>Koniaris LG, McKillop IH, Schwartz SI, Zimmers TA. Liver regeneration. J Am Coll Surg. 2003 Oct;197(4):634-59. Review.</citation>
    <PMID>14522336</PMID>
  </reference>
  <reference>
    <citation>Lorenz M, Staib-Sebler E, Gog C, Proschek D, Jauch KW, Ridwelski K, Hohenberger W, Gassel HJ, Lehmann U, Vestweber KH, Padberg W, Zamzow K, Müller HH. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir. 2003 Feb;128(2):87-94.</citation>
    <PMID>12632273</PMID>
  </reference>
  <reference>
    <citation>Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 Feb 8;322(6):352-8.</citation>
    <PMID>2300087</PMID>
  </reference>
  <reference>
    <citation>Nordlinger B, Sorbye H, Debois M, Praet M, Glimelius B, Poston GJ, P. Schlag M, Walpole ET, Bechstein W, Gruenberger T. Feasibility and risks of pre-operati ve chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3528.</citation>
  </reference>
  <reference>
    <citation>Portier G, Rougier P, Milan C et al. Adjuvant systemic chemotherapy using 5-fluorouracil and folinic acid after resection of liver metastases from colorectal origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002). Proc Am Soc Clin Oncol (2002); 20:528 (abstr).</citation>
  </reference>
  <reference>
    <citation>Reddy GK. The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer. 2005 Jan;4(5):300-1.</citation>
    <PMID>15663832</PMID>
  </reference>
  <reference>
    <citation>Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005 Sep 1;91(3):173-80.</citation>
    <PMID>16118771</PMID>
  </reference>
  <reference>
    <citation>Schemmer P, Friess H, Hinz U, Mehrabi A, Kraus TW, Z'graggen K, Schmidt J, Uhl W, Büchler MW. Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg. 2006 Mar;30(3):419-30.</citation>
    <PMID>16467982</PMID>
  </reference>
  <reference>
    <citation>Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006 Mar;202(3):468-75. Epub 2006 Jan 18.</citation>
    <PMID>16500252</PMID>
  </reference>
  <reference>
    <citation>Tabernero JM, Van Cutsem E, Sastre J, Cervantes A, Van Laethem JL, Humblet Y, Soulié P, Corretgé S, Mueser M, De Gramont A; Vall d'Hebron. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3512.</citation>
  </reference>
  <reference>
    <citation>Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol. 2005 Jan 20;23(3):502-9.</citation>
    <PMID>15659495</PMID>
  </reference>
  <reference>
    <citation>Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003 Aug;90(8):963-9.</citation>
    <PMID>12905549</PMID>
  </reference>
  <reference>
    <citation>Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-72.</citation>
    <PMID>16648507</PMID>
  </reference>
  <reference>
    <citation>Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, Benson A, Wade J, Schilsky R, Mayer R. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3509.</citation>
  </reference>
  <reference>
    <citation>Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006 May;13(5):668-76. Epub 2006 Mar 10.</citation>
    <PMID>16523369</PMID>
  </reference>
  <reference>
    <citation>Wolmark N, Wieand S, Kuebler JP, Colangelo L, and Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. ASCO Meeting Abstracts 2005 23.</citation>
  </reference>
  <reference>
    <citation>Yedibela S, Elad L, Wein A, Dimmler A, Merkel S, Hohenberger W, Meyer T. Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases. Eur J Surg Oncol. 2005 Mar;31(2):141-6.</citation>
    <PMID>15698729</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <results_first_submitted>August 31, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2016</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on 06/06/2007 and closed to participants enrollment on 11/03/2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 - Wildtype</title>
          <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m2 IV weekly</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
          <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Week 7
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Week 7, 15
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 - Wildtype</title>
          <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m2 IV weekly</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
          <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Week 7
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2
Week 7, 15
Leucovorin 400 mg/m2 IV
Oxaliplatin 85 mg/m2 IV
5FU bolus 400 mg/m2
5FU CIVI 1200 mg/m2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="44" upper_limit="70"/>
                    <measurement group_id="B2" value="62" lower_limit="47" upper_limit="77"/>
                    <measurement group_id="B3" value="62" lower_limit="44" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Complication Rate</title>
        <description>Fraction of patients with any grade of complication I-V</description>
        <time_frame>30 days following surgery</time_frame>
        <population>4 participants did not have surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Complication Rate</title>
          <description>Fraction of patients with any grade of complication I-V</description>
          <population>4 participants did not have surgery.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Postoperative Complication Rate</title>
        <description>Fraction of patients with any complication grades IV and V</description>
        <time_frame>30 days following surgery</time_frame>
        <population>4 participants did not have surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Major Postoperative Complication Rate</title>
          <description>Fraction of patients with any complication grades IV and V</description>
          <population>4 participants did not have surgery.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality</title>
        <time_frame>30 days following surgery</time_frame>
        <population>4 participants did not have surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <population>4 participants did not have surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Recurrence Patterns</title>
        <description>Liver only vs distant disease</description>
        <time_frame>Up to 5 years</time_frame>
        <population>7 participants were not evaluable. 4 participants did not have surgery (3 in Arm 1, 1 in Arm 2). 1 participant had surgery but was not resectable (Arm 1) . 1 participant developed another primary cancer (Arm 1). 1 participant died before recurrence from hepatic failure (Arm 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Recurrence Patterns</title>
          <description>Liver only vs distant disease</description>
          <population>7 participants were not evaluable. 4 participants did not have surgery (3 in Arm 1, 1 in Arm 2). 1 participant had surgery but was not resectable (Arm 1) . 1 participant developed another primary cancer (Arm 1). 1 participant died before recurrence from hepatic failure (Arm 1).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histologic Hepatic Toxicity at Surgery</title>
        <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
        <population>4 participants did not have surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Hepatic Toxicity at Surgery</title>
          <population>4 participants did not have surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not reported on pathology report</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nonalcoholic Steatohepatitis Score (0-3)</title>
        <description>NASH Scoring
Steatosis **&lt;5% = 0
**5-33%=1
**&gt;33-66%=2
**&gt;66%=3
Lobular inflammation
**No foci=0
**&lt;2 foci per x 200 field=1
**2-4 foci per x 200 field=2
**&gt;4 foci per x 200 field=3
Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2</description>
        <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
        <population>4 participants did not have surgery and are not included in this outcome measure.
The study pathologist left the university early prior to completion of study pathology for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Nonalcoholic Steatohepatitis Score (0-3)</title>
          <description>NASH Scoring
Steatosis **&lt;5% = 0
**5-33%=1
**&gt;33-66%=2
**&gt;66%=3
Lobular inflammation
**No foci=0
**&lt;2 foci per x 200 field=1
**2-4 foci per x 200 field=2
**&gt;4 foci per x 200 field=3
Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2</description>
          <population>4 participants did not have surgery and are not included in this outcome measure.
The study pathologist left the university early prior to completion of study pathology for this study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not reported on pathology report</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Injury Scale Score (0-27)</title>
        <time_frame>Time of surgery (approximately 11-16 weeks)</time_frame>
        <population>Data was not collected for this outcome measure as the study pathologist left the institution early prior to study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Injury Scale Score (0-27)</title>
          <population>Data was not collected for this outcome measure as the study pathologist left the institution early prior to study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Preoperative Chemotherapy on Tumor Size</title>
        <description>Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy.</description>
        <time_frame>Upon completion of neoadjuvant chemotherapy (approximately 2 months)</time_frame>
        <population>2 participants did not have the CT scan prior to surgery as both did not complete preoperative chemotherapy due to adverse skin reactions to cetuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Preoperative Chemotherapy on Tumor Size</title>
          <description>Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy.</description>
          <population>2 participants did not have the CT scan prior to surgery as both did not complete preoperative chemotherapy due to adverse skin reactions to cetuximab.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Size From Pretreatment to Preoperative CT Scan</title>
        <description>-Compare total longest diameter from baseline to preoperative CT scan.</description>
        <time_frame>Completion of neoadjuvant therapy (approximately 8 weeks)</time_frame>
        <population>2 participants did not have the CT scan prior to surgery as both did not complete preoperative chemotherapy due to adverse skin reactions to cetuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Wildtype</title>
            <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
            <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Size From Pretreatment to Preoperative CT Scan</title>
          <description>-Compare total longest diameter from baseline to preoperative CT scan.</description>
          <population>2 participants did not have the CT scan prior to surgery as both did not complete preoperative chemotherapy due to adverse skin reactions to cetuximab.</population>
          <units>percentage of change of longest diameter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" lower_limit="-71.7" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-14.3" lower_limit="-28.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - Wildtype</title>
          <description>Neoadjuvant therapy
Week 1
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
Weeks 3, 5, 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Week 1, 3, 5, 7, 9, 11, 13, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2/day over 46 hours
Weeks 2, 4, 6, 8, 10, 12, 16
*Cetuximab 250 mg/m^2 IV weekly</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 K-Ras 12/13 Codon Mutation</title>
          <description>Neoadjuvant Therapy
Weeks 1, 3, 5
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Wait 3-8 weeks after completion of therapy
Liver resection
Wait 4 weeks or until clinical status allows
Adjuvant Therapy
Weeks 1, 3, 5, 9, 11, 13
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
Bevacizumab 5 mg/kg IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2
Week 7, 15
Leucovorin 400 mg/m^2 IV
Oxaliplatin 85 mg/m^2 IV
5FU bolus 400 mg/m^2
5FU CIVI 1200 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Liver dysfunction failure (cholestatic jaundice)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain - GI (Abdomen NOS)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Digestive problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucositis (oral cavity)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucositis (stomach)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Other (Liver pain)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection grade 1/2 normal ANC - general (wound)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection grade 1/2 normal ANC - pulmonary (sinus)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection grade 1/2 normal ANC - pulmonary (up airway)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Elevated PT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Slight puffiness in right upper lip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Musculoskeletal (Back)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain - Musculoskeletal (Limb)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle weakness - whole body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain - Neurology (Headache)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neuropathy (motor)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Resp-bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain - Pulmonary (Throat)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hemorrhage (resp-nose)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Linehan, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <email>David_Linehan@URMC.Rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

